Prospective Cohort Study of Gastrointestinal Complications and Vascular Diseases in Patients Taking Aspirin: Rationale and Design of the MAGIC Study
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Hideki Origasa , Shinya Goto , Kazuyuki Shimada , Shinichiro Uchiyama , Yasushi Okada , Kentaro Sugano , Hideyuki Hiraishi , Naomi Uemura , Yasuo Ike
- چاپ و سال / کشور: 2011
Description
Objective Although aspirin has been widely prescribed for the prevention of cardiovascular events, its risk of gastrointestinal complications is of great concern. Despite expectations for such, few data are available on the prevalence or incidence of gastrointestinal complications in aspirin users in Japan. The Management of Aspirin-induced GastroIntestinal Complications (MAGIC) is the first attempt at collaboration among cardiologists, neurologists, and gastroenterologists to obtain such findings. We aim to share all about the MAGIC study. Methods TheMAGIC is a prospective cohort study involving patients taking low-dose aspirin (81 mg to 325 mg per day) for longer than 1 month. Participants are recruited from multiple disease categories, including those with coronary artery disease, cerebrovascular disease, atrial fibrillation, and other cardiovascular conditions requiring antithrombotic therapy. Its duration of follow-up is 1 year. At baseline and 1 year followup, all participants will undergo endoscopic examination. The primary outcome is upper gastrointestinal complications, classified as erosions, ulcers, and bleeding. Secondary outcomes include LANZA score, non-fatal cardiovascular events, any bleeding, cancer, and death. Results 1,533 participants were entered in the MAGIC cohort. By underlying disease, about 45% of them hadcoronary artery diseases, followed by cerebrovascular diseases (35%), atrial fibrillation (10%) and other cardiovascular diseases (10%). Conclusions The MAGIC study will yield important findings with regard to the prevalence and incidence of gastrointestinal complications and related risk factors for low-dose aspirin users. It may also report that use of antisecretory agents such as proton pump inhibitors reduces the risk of such complications.
Cardiovasc Drugs Ther DOI 10.1007/s10557-011-6328-2
